Brokerages forecast that Scholar Rock Holding Corp (NASDAQ:SRRK) will post earnings per share (EPS) of ($0.48) for the current quarter, Zacks reports. Zero analysts have made estimates for Scholar Rock’s earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.46). The company is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Scholar Rock will report full year earnings of ($3.68) per share for the current financial year, with EPS estimates ranging from ($5.48) to ($1.88). For the next fiscal year, analysts forecast that the company will post earnings of ($1.95) per share, with EPS estimates ranging from ($2.40) to ($1.18). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Scholar Rock.

SRRK has been the topic of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Scholar Rock in a research note on Friday, November 9th. Cowen reaffirmed a “buy” rating on shares of Scholar Rock in a research note on Monday, November 12th. Finally, Zacks Investment Research raised Scholar Rock from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Friday, November 16th. Five research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $26.75.

Scholar Rock stock traded down $0.17 during trading hours on Monday, hitting $16.34. The stock had a trading volume of 310 shares, compared to its average volume of 71,437. Scholar Rock has a 1-year low of $13.09 and a 1-year high of $30.00.

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Scholar Rock during the 3rd quarter valued at about $9,485,000. Vanguard Group Inc raised its holdings in shares of Scholar Rock by 479.1% during the 3rd quarter. Vanguard Group Inc now owns 231,656 shares of the company’s stock valued at $5,966,000 after buying an additional 191,656 shares during the period. Vanguard Group Inc. raised its holdings in shares of Scholar Rock by 479.1% during the 3rd quarter. Vanguard Group Inc. now owns 231,656 shares of the company’s stock valued at $5,966,000 after buying an additional 191,656 shares during the period. BB Biotech AG purchased a new stake in shares of Scholar Rock during the 3rd quarter valued at about $4,891,000. Finally, Millennium Management LLC purchased a new stake in shares of Scholar Rock during the 2nd quarter valued at about $1,349,000. Institutional investors own 50.78% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy.

Featured Article: Insider Trading – What You Need to Know

Get a free copy of the Zacks research report on Scholar Rock (SRRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.